| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | Parafibromin (Cell division cycle protein 73 homolog; Hyperparathyroidism 2 protein) |
| Entrez GeneID | 79577 |
| WB Predicted band size | Calculated MW: 61 kDa; Observed MW: 61 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Synthesized peptide derived from human Parafibromin. at AA range: 51-100 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3-4条关于HRPT2抗体的模拟参考文献示例(内容为模拟创作，建议通过学术数据库获取真实文献)：
---
1. **文献名称**：*HRPT2 mutations and parathyroid cancer*
**作者**：Howell VM, et al.
**摘要**：研究分析了HRPT2基因突变在甲状旁腺癌中的作用，通过HRPT2抗体检测发现突变导致其编码蛋白(parafibromin)表达缺失，提示其在肿瘤抑制中的关键功能。
2. **文献名称**：*Immunohistochemical detection of parafibromin in hyperparathyroidism*
**作者**：Tan MH, Gill AJ
**摘要**：开发了一种基于HRPT2抗体的免疫组化方法，用于鉴别遗传性甲状旁腺功能亢进症(HPT-JT综合征)和散发性肿瘤，证明parafibromin表达缺失与HRPT2突变高度相关。
3. **文献名称**：*HRPT2/CDC73 interactions with β-catenin regulate Wnt signaling*
**作者**：Cetani F, et al.
**摘要**：利用HRPT2抗体研究parafibromin与Wnt/β-catenin通路的相互作用，发现HRPT2缺失导致β-catenin异常激活，促进肿瘤发生。
4. **文献名称**：*Molecular pathogenesis of HRPT2-related diseases*
**作者**：Marx SJ, et al.
**摘要**：综述HRPT2基因突变引起的疾病谱，包括使用HRPT2抗体在临床诊断中的应用，强调其在遗传性甲状旁腺疾病和肾肿瘤中的价值。
---
建议通过 **PubMed、Google Scholar** 或 **Web of Science** 检索真实文献，关键词可尝试：
- "HRPT2 antibody parafibromin"
- "HRPT2 mutation immunohistochemistry"
- "CDC73 (HRPT2) molecular pathology"
The HRPT2 antibody is designed to detect parafibromin, a protein encoded by the *HRPT2* gene (also known as *CDC73*), which functions as a tumor suppressor. Mutations in *HRPT2* are linked to hyperparathyroidism-jaw tumor (HPT-JT) syndrome, a rare autosomal dominant disorder characterized by parathyroid adenomas/carcinomas, ossifying fibromas of the jaw, and renal cysts. Parafibromin plays a role in transcriptional regulation, cell cycle control, and Wnt signaling, with loss of expression often associated with malignant transformation in parathyroid tumors.
HRPT2 antibodies are primarily used in research and diagnostics to assess parafibromin expression via immunohistochemistry (IHC) or Western blotting. In clinical settings, loss of nuclear parafibromin staining aids in distinguishing parathyroid carcinomas from benign adenomas, as somatic *HRPT2* mutations are prevalent in sporadic parathyroid cancers. These antibodies also help identify carriers of germline *HRPT2* mutations in families with HPT-JT syndrome, enabling early surveillance.
Available as monoclonal or polyclonal variants, HRPT2 antibodies require validation for specificity due to potential cross-reactivity. Their utility extends to studying parafibromin's molecular interactions and dysregulation in other cancers, such as renal and uterine tumors. Overall, HRPT2 antibodies are critical tools for understanding tumorigenesis mechanisms and guiding clinical management of *HRPT2*-related disorders.
×
